Stockscreener 앱 받기
29.54
2.29%
0.66
시간 외 거래:
29.50
-0.04
-0.14%
전일 마감가:
$28.88
열려 있는:
$29.17
하루 거래량:
26,033
Relative Volume:
0.47
시가총액:
$28.89M
수익:
-
순이익/손실:
$-33.04M
주가수익비율:
-3.2453
EPS:
-9.1023
순현금흐름:
$-39.66M
1주 성능:
+28.27%
1개월 성능:
+73.97%
6개월 성능:
+6.18%
1년 성능:
-91.10%
1일 변동 폭
$28.55
$30.32
1주일 범위
$21.55
$30.32
52주 변동 폭
$15.10
$909.98
Quince Therapeutics Inc Stock (QNCX) Company Profile
명칭
Quince Therapeutics Inc
전화
415-910-5717
주소
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
29.54 | 17.46M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
484.03 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
772.11 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
875.30 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
197.81 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
329.80 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-08-05 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-03-24 | 개시 | Oppenheimer | Outperform |
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quince Therapeutics Inc (QNCX) Institutional Confidence - TradingKey
Quince Therapeutics Inc (QNCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quince Therapeutics, Inc. Revenue Breakdown – NASDAQ:QNCX - TradingView
QNCX|Quince Therapeutics Inc|Price:17.740|Chg%:-0.540 - TradingKey
QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
Quince Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Driven by One-Time GainEarnings Forecast Report - dars.gov.et
QNCX Q1 2026 Earnings: Stunning EPS Surprise of 210.29% as Company Reports $57.6 Per Share - dars.gov.et
Quince Therapeutics Surges Over 11% as Biotech Momentum BuildsAdvance Decline Line - dars.gov.et
QNCX Q1 2026 Earnings: EPS Surges to $57.6, Crushing Estimates Amid Strong Stock ReactionEarnings Revision Report - dars.gov.et
Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug - Ad Hoc News
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - The National Law Review
QNCX Should I Buy - Intellectia AI
What date does Quince Therapeutics, Inc.'s (QNCX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
$Quince Therapeutics (QNCX.US)$ fake news !!! - Moomoo
HCW Biologics Inc.: Top Mutual Funds Holders | QNCX | US40423R3030 - marketscreener.com
QNCX Q1 2026 Earnings: Massive EPS Surprise Amid Stock Decline Raises QuestionsDiluted EPS Report - dars.gov.et
Quince Therapeutics forms advisory board for LAM-001 drug - Investing.com
Quince Therapeutics forms advisory board for LAM-001 drug By Investing.com - Investing.com India
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board - GlobeNewswire
LifeSci Capital Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $100 - Moomoo
Quince Therapeutics Implements 1-for-20 Reverse Stock Split - The Globe and Mail
Quince Therapeutics, Inc. Files 8-K/A Amendment to Correct Reverse Stock Split Description – Key SEC Filing Details - Minichart
Quince Therapeutics Inc. (QNCX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Quince Therapeutics (QNCX) confirms 1-for-20 reverse split and sharp share reduction - Stock Titan
1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares - Stock Titan
Price to sales forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Enterprise value to revenue forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Price to book forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Price to earnings forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Enterprise value to EBIT forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics, Inc. Actuals & Estimates (NASDAQ:QNCX) - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating By Investing.com - Investing.com South Africa
QNCX Forecast — Price Target — Prediction for 2027 - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight - Investing.com
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating - Investing.com
Cantor Fitzgerald Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
$Quince Therapeutics (QNCX.US)$ - Moomoo
QNCX Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Leerink initiates Quince Therapeutics stock with Outperform rating By Investing.com - Investing.com Australia
Leerink Partners Initiates Quince Therapeutics at Outperform With $4 Price Target - marketscreener.com
Leerink initiates Quince Therapeutics stock with Outperform rating - Investing.com
QNCX Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
Quince Therapeutics Inc (QNCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Quince Therapeutics Inc 주식 (QNCX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
1.19%
1.50%
자본화:
|
볼륨(24시간):